FDA Grants Full Approval to Datopotamab Deruxtecan for Metastatic Triple-Negative Breast Cancer

The FDA's approval on May 22, 2026, of datopotamab deruxtecan—marketed under the brand name Datroway—marks a watershed moment for patients facing one of the most aggressive and historically difficult-to-treat forms of breast cancer. The regulatory agency granted full approval to the targeted therapy for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 immunotherapy. This decision establishes a powerful new first-line defense for a patient population that has long been forced to rely on conventional, broad-spectrum chemotherapy.[1][2]

For decades, metastatic TNBC has been a notoriously difficult disease to treat due to its unique cellular profile. Unlike other forms of breast cancer, TNBC tumors lack estrogen receptors, progesterone receptors, and the HER2 protein. Because the cancer cells are missing these three key biological markers, they simply do not respond to the highly effective hormone-blocking drugs or HER2-targeted therapies that have dramatically improved survival rates and quality of life for other breast cancer populations. This biological reality has made TNBC the most challenging breast cancer subtype to manage.

Consequently, patients diagnosed with metastatic TNBC have historically been left with conventional, systemic chemotherapy as their primary and often only option. While chemotherapy can be effective initially at shrinking tumors, it frequently fails to control the disease for long periods and carries a heavy burden of broad systemic toxicity that degrades a patient's quality of life. The approval of datopotamab deruxtecan introduces a fundamentally different approach to the disease, offering a highly targeted mechanism that spares more healthy tissue while delivering a lethal, concentrated blow directly to the tumors.[3]

Datopotamab deruxtecan belongs to a rapidly advancing and highly successful class of medications known as antibody-drug conjugates (ADCs). Oncologists frequently describe ADCs as 'smart bombs' because of their precision-guided approach to eradicating cancer cells. The drug consists of a specialized monoclonal antibody engineered to seek out and bind to TROP2, a specific protein that is heavily overexpressed on the surface of most TNBC cells, while remaining largely absent from healthy tissue. This targeted binding ensures that the medication circulates through the bloodstream harmlessly until it encounters a tumor cell displaying the TROP2 marker, at which point it locks on and initiates the destruction process.

Once the antibody firmly attaches to the TROP2 receptor on the outside of the cancer cell, the entire molecule is drawn inside the cell membrane. Only then does the ADC release its payload—a highly potent chemotherapy agent called a topoisomerase I inhibitor. By delivering the chemotherapy directly into the interior of the cancer cell, the drug maximizes tumor destruction from the inside out while minimizing the collateral damage to healthy organs and tissues that is typically associated with traditional, untargeted chemotherapy infusions.[4]

The FDA's landmark decision was anchored by the compelling results of the global Phase 3 TROPION-Breast02 clinical trial, which enrolled 644 patients with unresectable or metastatic TNBC. The trial participants, who had not received prior systemic therapy for their metastatic disease and were ineligible for immunotherapy, were randomized to receive either datopotamab deruxtecan or the investigator's choice of standard single-agent chemotherapy. The rigorous trial design aimed to definitively prove whether the new ADC could outperform the long-standing standard of care in a head-to-head comparison.[1][2]

The trial data, which was published in the prestigious Annals of Oncology, demonstrated a profound efficacy advantage for the new antibody-drug conjugate. The drug reduced the overall risk of disease progression or death by a remarkable 43 percent compared to standard chemotherapy. Median progression-free survival—the length of time patients lived without their cancer worsening or spreading further—nearly doubled, reaching 10.8 months in the datopotamab deruxtecan arm versus just 5.6 months in the chemotherapy control arm. This extension of progression-free time is critical for patients, offering them nearly a year of disease stability and improved quality of life before needing to explore subsequent lines of treatment.[1][4]

Even more critically, the targeted therapy delivered a statistically significant and clinically meaningful improvement in overall survival, which is the ultimate gold standard for oncology trials. Patients receiving datopotamab deruxtecan lived for a median of 23.7 months, a full five months longer than the 18.7-month median survival observed in the chemotherapy group. In the landscape of metastatic TNBC, where survival gains are historically measured in mere weeks rather than months, a five-month extension represents a monumental leap forward in disease management.[2]

Beyond extending survival, the drug also proved vastly superior at actively shrinking existing tumors. The confirmed overall response rate was 64 percent for patients treated with the ADC, meaning nearly two-thirds of patients saw their tumors measurably decrease in size. This was more than double the 30 percent response rate seen in patients receiving standard chemotherapy, highlighting the sheer potency of delivering the topoisomerase I inhibitor directly into the TROP2-expressing cancer cells. For patients suffering from symptomatic tumors, this rapid and significant shrinkage can translate immediately into pain relief and improved daily functioning.[1][2]

Dr. Tiffany A. Traina, Section Head for the TNBC Clinical Research Program at Memorial Sloan Kettering Cancer Center and a lead investigator on the trial, emphasized the historic nature of the data. She noted that datopotamab deruxtecan is the first and only medicine to significantly prolong overall survival in the first-line setting compared to chemotherapy for this specific patient group. She emphasized that the approval brings a much-needed, highly effective option to a population that has long relied on conventional chemotherapy as their only defense.[3]

Dr. Rena D. Callahan, a breast medical oncologist at UCLA Health, echoed the profound significance of the survival data for the TNBC community. She pointed out that while oncologists frequently see patients with HER2-positive or hormone receptor-positive metastatic disease survive for six years or more on targeted therapies, such longevity is exceedingly rare in TNBC. The introduction of a targeted TROP2-directed ADC fundamentally alters the long-term prognosis for these patients, offering a bridge to longer survival that was previously out of reach.[2]

Despite its highly targeted nature, datopotamab deruxtecan is not without risks, and oncologists must manage its unique toxicity profile carefully. The FDA prescribing information includes strict warnings and precautions for interstitial lung disease (ILD) and pneumonitis, which are known, potentially severe side effects associated with the broader ADC drug class. Patients must be closely monitored for respiratory symptoms such as coughing or shortness of breath, and the treatment may need to be interrupted or permanently discontinued if lung inflammation occurs.[1][3]

Other notable adverse reactions reported during the clinical trials include stomatitis (oral mucositis), ocular toxicities, and embryo-fetal toxicity. However, clinical investigators note that the overall safety profile is generally manageable with proactive supportive care. Many patients actually prefer the side-effect profile of the ADC over the cumulative fatigue, severe neuropathy, and broad gastrointestinal toxicity associated with multi-agent conventional chemotherapy regimens, allowing them to maintain a higher quality of life during treatment. The shift from broad toxicity to specific, monitorable side effects represents a major improvement in the patient experience.[1][2]

The drug is administered as an intravenous infusion once every three weeks, with dosing carefully calculated based on the patient's body weight. The FDA's review of the therapy was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence that provides a framework for the concurrent submission and review of oncology drugs among international partners, ensuring that breakthrough therapies reach global populations more rapidly. This collaborative regulatory approach highlights the overwhelming consensus among global health authorities regarding the drug's efficacy and the urgent unmet need it addresses.[1]

The global impact of the TROPION-Breast02 data is already materializing across international borders. In June 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending the drug's approval in the EU. With additional regulatory reviews actively underway in Australia, Canada, Switzerland, and Singapore, datopotamab deruxtecan is rapidly establishing a new global standard of care, transforming one of oncology's most formidable challenges into a highly treatable condition. As the drug rolls out to clinics worldwide, it brings renewed hope to thousands of patients who previously faced a dire prognosis.[1]